ARTICLE AD BOX
Mumbai: Pharmaceutical major Wockhardt Limited has achieved a historical milestone with the US Food and Drug Administration (USFDA) approving its breakthrough novel antibiotic, Zaynich.
This comes after Wockhardt became the first Indian pharma company to file a New Drug Application (NDA) with the US FDA last year, and has shown how the domestic pharma sector is slowly moving beyond manufacturing copycat generic drugs based on established formulations.
The company has taken more than two decades to develop Zaynich through a targeted Research and Development (R&D) campaign and seen success that could rival that of Novo Nordisk’s Ozempic weight loss drug.
With the US approval in place, Zaynich could become the golden egg-laying hen for Wockhardt, given the increasing challenge of antibiotic resistance(AMR) that doctors worldwide have been grappling with.
Unlike Ozempic, which is targeted towards lifestyle diseases, AMR is a growing health challenge faced by millions, as disease-causing viruses have become increasingly resistant to conventional antibiotics and drug therapies. With Zaynich becoming the only player in this niche, there is high hopes that it could solve a global healthcare crises for a long time.
On receiving the news, Wockhardt’s stock surged up to 16% as the markets validated the immense potential of this development for Wockhardt’s market value, even as the stock has rallied over 60% in the last 30 days in anticipation of the news.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in stocks includes financial risks, and past performance is not indicative of future results. Readers should conduct their own research or consult with a qualified financial advisor before making any investment decisions.
English (US) ·